5月7日 - ** Insmed INSM.O 股价盘前下跌 5.9%，报 128.99 美元
** 据路孚特（LSEG）数据显示，这家制药公司报告称，其肺部疾病治疗药物Arikayce第一季度销售额为9810万美元，低于分析师平均预期的1.054亿美元
** INSM表示，公司正持续评估美国政策变化的潜在影响，这些变化将进而影响其另一款肺病治疗药物Brinsupri的国际上市时间
** 公司季度营收3.06亿美元，高于分析师预期的3.03亿美元
** 截至上一交易日收盘，该股年内累计跌幅达21.2%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.